The National Cancer Institute (NCI) awarded a $562,869 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to Children's Hospital Los Angeles (CHLA) to study the role of chromosome 17q gain in the development and progression of neuroblastoma, the most common pediatric extracranial solid tumor. The 5-year grant funding will support a research project using human stem cell models to: 1) compare the tumorigenic potential of 17q gain and MYCN oncogene activation in immature cells that give rise to sympathoadrenal cells, 2) determine genes on chromosome 17q that cooperate with MYCN to accelerate tumorigenesis and promote chemotherapy resistance, and 3) identify vulnerabilities in MYCN/17q+ neuroblastoma tumors. Successful completion of this research aims to provide critical insights into the role of chromosome 17q gain in neuroblastoma and identify new therapeutic approaches to overcome chemotherapy resistance.
Generated 3/4/25, 2:52 AM